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Abstract
Background: The novel influenza A pandemic virus (H1N1pdm) caused considerable morbidity and mortality worldwide in
2009. The aim of the present study was to evaluate the clinical course, duration of viral shedding, H1N1pdm evolution and
emergence of antiviral resistance in hospitalized cancer patients with severe H1N1pdm infections during the winter of 2009
in Brazil.
Methods: We performed a prospective single-center cohort study in a cancer center in Rio de Janeiro, Brazil. Hospitalized
patients with cancer and a confirmed diagnosis of influenza A H1N1pdm were evaluated. The main outcome measures in
this study were in-hospital mortality, duration of viral shedding, viral persistence and both functional and molecular
analyses of H1N1pdm susceptibility to oseltamivir.
Results: A total of 44 hospitalized patients with suspected influenza-like illness were screened. A total of 24 had diagnosed
H1N1pdm infections. The overall hospital mortality in our cohort was 21%. Thirteen (54%) patients required intensive care.
The median age of the studied cohort was 14.5 years (3–69 years). Eighteen (75%) patients had received chemotherapy in
the previous month, and 14 were neutropenic at the onset of influenza. A total of 10 patients were evaluated for their
duration of viral shedding, and 5 (50%) displayed prolonged viral shedding (median 23, range = 11–63 days); however, this
was not associated with the emergence of a resistant H1N1pdm virus. Viral evolution was observed in sequentially collected
samples.
Conclusions: Prolonged influenza A H1N1pdm shedding was observed in cancer patients. However, oseltamivir resistance
was not detected. Taken together, our data suggest that severely ill cancer patients may constitute a pandemic virus
reservoir with major implications for viral propagation.
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Introduction
The emergence of the novel influenza A/H1N1 pandemic virus
(H1N1pdm) significantly affected the utilization of healthcare
resources and increased morbidity and mortality in children and
young adults [1,2]. From April through September 2009, during
the fall/winter in the southern hemisphere, Brazil experienced the
first wave of the H1N1pdm virus, and by the end of December
2009, over 1600 H1N1pdm-related deaths had been reported in
Brazil [3].
Emerging data on the clinical course of severe H1N1pdm
infection have allowed the identification of high-risk groups, which
include pregnant women and patients with morbid obesity [4,5].
However, an analysis of the impact of this novel virus in a highly
susceptible population, such as cancer patients, through clinical and
virological perspectives, needs to be highlighted [6,7,8,9,10,11]. The
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atypical clinical presentation of influenza infections in cancer
patients, which delays clinical suspicion, antiviral treatment and
adequate prevention of viral transmission, is a major challenge for
clinical management in this population [12]. Cancer patients are
more likely to suffer from severe seasonal influenza infections
[12,13,14] and prolonged viral shedding, as has been reported for an
H3N2 seasonal virus [15]. Prolonged shedding and the development
of oseltamivir resistance in cancer patients infected with the
H1N1pdm virus have not been thoroughly evaluated. Data on
these aspects could have major implications for the clinical
management and infection control practices for H1N1pdm-infected
cancer patients [16].
Because the analysis of this novel viral infection in cancer patients
is an important component of the 2009 pandemics, we conducted a
prospective cohort study aimed at evaluating the clinical course of
influenza infection, the duration of viral shedding, H1N1pdm
evolution and the emergence of antiviral resistance in hospitalized
cancer patients with a severe H1N1pdm infection in a reference
cancer center during the winter of 2009 in Brazil.
Results
Characteristics of the study population
During the study period, 44 hospitalized cancer patients with a
suspected influenza infection were screened, and 24 had a
confirmed influenza A diagnosis using a rapid indirect immuno-
fluorescence (IFI) test or World Health Organization (WHO)-
recommended real-time RT-PCR (rRT-PCR) (Figure 1 and Table
S1). Among these, 20 patients were confirmed to be positive for
the H1N1pdm virus using rRT-PCR (Figure 1 and Table S1). The
remaining four patients were positive for influenza A using IFI
only. Considering the pandemic case definitions with reference to
international guidelines [17], these last four cases were categorized
as H1N1pdm-confirmed cases. Altogether, these 24 cases
constituted the study population. All of the respiratory samples
collected from the 20 rRT-PCR-confirmed patients were inocu-
lated in cell cultures. We recovered the virus from 13 individuals
after at least two passages in MDCKs, constituting 15 isolated
samples. These isolates were also analyzed for oseltamivir
resistance using a functional assay.
Patients diagnosed with H1N1pdm were young (median age
= 14.5, range 3–69 years). In total, 14 (58.3%) were under 18 years
old, and 17 (70.8%) were less than 50 years old. Hematologic
cancer occurred in 75% (18) of the patients, whereas solid tumors
occurred in 25% (6) patients (Tables S2 and S3). A total of 22
(,92%) patients had received immunosuppressive therapy in the
previous 30 days. Among these individuals, 18 patients (75%) were
on chemotherapy, 14 (58.3%) received systemic corticosteroids
and 1 (4%) received radiation therapy (Table 1 and S4). No
patient received erythropoietin (EPO) or immunomodulatory
agents. A total of 14 patients (58.3%) presented febrile neutropenia
(,500 neutrophils/mm3) at the time H1N1pdm was diagnosed.
The median duration of neutropenia after the onset of viral disease
was two days (ranging from one to six days; Table S5). According
to the Brazilian National Cancer Institute’s protocol, all patients
that presented neutropenia received G-CSF until normalization of
neutrophil counts. The clinical characteristics and comparisons
among groups are shown in Table 1 and Tables S1, S2, S3, S4,
S5, S6, S7, S8, S9, S10, and S11. The overall mortality in our
cohort was around 21% (n = 5), and four patients (n = 16.6%) had
at least one comorbidity besides cancer. Of these patients with
comorbidities, one died. No pregnant or morbidly obese patients
were identified.
A total of 23 (95.8%) patients were treated with oseltamivir, and
the median time from the initial symptoms to the initiation of
therapy was three days (0–15 days; Tables 1, S2 and S6). One
patient that died due to severe acute respiratory failure 24 h after
clinical suspicion of H1N1pdm infection never received antiviral
treatment. Oseltamivir was used for a median of seven days (0–19
days), and double doses (150 mg bid for adults and twice the
recommended dose per kg for children) were administered for 11
(47.8%) patients (Table S6). A total of 11 (47.8%) patients received
oseltamivir for more than seven days. Six patients (25%) received
this antiviral within 48 h of clinical suspicion. All patients that died
received oseltamivir more than 48 h after the onset of the illness.
However, when we compared the mortality of patients that
Figure 1. Study flow chart.
doi:10.1371/journal.pone.0014158.g001
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received oseltamivir either within or after 48 h of the onset illness,
no significant difference was observed (0/6 vs. 5/18, p = 0.28). No
differences in prolonged viral shedding were observed between
these two groups.
At presentation, all patients were treated with broad-spectrum
intravenous antimicrobial agents to combat community-acquired
pneumonia and/or febrile neutropenia [18], and five (20.8%) had
concomitant positive cultures (Tables S7 and S8). Hypoxemia was
frequent, and the median PaO2/FiO2 on the first arterial blood
gas evaluation was 192 mmHg (range: 64–367 mmHg).
Intensive care unit admission
Overall, 13 patients (five adults and eight children) were
admitted to the ICU. Six patients were directly admitted from the
emergency department, and the other seven patients were
transferred from other hospital wards (Table S2). Ventilatory
support was given to 12 patients (Table 1 and S9). Invasive
mechanical ventilation was performed in 10 patients (76.9%), and
non invasive ventilation (NIV) was performed in 3 patients (23.1%;
Table 1). Among the NIV patients, one required subsequent
endotracheal intubation and mechanical ventilation, and all three
patients were discharged from the hospital. Extra-pulmonary
organ failure occurred in eight patients (33.3%; Table 1 and S9).
Of the 13 critically ill patients, 12 were treated with oseltamivir,
and treatment was initiated 48 h after the first signs/symptoms of
viral infection in 5 of them. Adjunct or non-conventional
supportive therapies for ARDS were performed for 12 of the 13
patients that entered the ICU (92.3%). A total of 10 patients
(76.9%) received systemic corticosteroids (eight due to previous use
and two for shock and persistent ARDS); five (38.5%) were
ventilated in a prone position, and four (30.8%) required
recruitment maneuvers. No patient received extra-corporeal
membrane oxygenation.
Prolonged H1N1pdm shedding
Although prolonged influenza A shedding has been observed for
a cancer patient infected with the H3N2 seasonal virus [15], more
detailed data on H1N1pdm secretion in severely ill cancer patients
are required. We evaluated viral shedding in 10 mechanically
ventilated patients by collecting sequential respiratory samples at
different time-points after the onset of illness. The duration of viral
shedding was considered to be the time frame from the initial
symptoms to the last H1N1pdm-confirmed sample. Five (50%)
patients in this group showed viral shedding for at least 11 days
during oseltamivir treatment (Figure 2 and Table S12). The
median duration of H1N1pdm shedding was 23 days (ranging
from 11 to 63 days; Figure 2 and Table S12).
Most importantly, the maximum duration of H1N1pdm
shedding in our investigation was 63 days, followed by 44 days
for another patient. To our knowledge, these periods constitute the
longest registered cases of H1N1pdm shedding described to date.
All rRT-PCR-positive samples from these patients with the longest
viral shedding durations (5645 and 5899) were culturable,
meaning that these were infectious viruses (Figure 2 and Table
S12). In addition, the last H1N1pdm-confirmed samples from
these patients were only detected using cell culture assays,
suggesting the presence of low viral loads in these specimens
(Figure 2 and Table S12). These patients still shed the virus for an
additional 25 to 40 days after cessation of the antiviral treatment
(Figure 2).
H1N1pdm molecular evolution in clinical isolates
To date, no significant variation has been detected at the amino
acid level in the hemagglutinin (HA) of the 2009 pandemic virus
[19]. Therefore, we examined the genetic diversity of the
H1N1pdm virus recovered from these severely ill patients by
performing sequence analysis of the viral HA gene. No significant
Table 1. Patient characteristics according to survival statusa.
Variable
All patients
(n =24)
Survivors
(n =19–79.2%)
Non-survivors
(n=5–20.8%) P value b
Age (years) 14.5 (3–69) 14 (3–69) 17 (4–62) 0.50
Male gender 12 (50%) 7 (36.8%) 5 (100%) 0.03
Type of cancer
Solid tumor 6 (25%) 5 (26.3%) 1 (20%) 0.99
Hematological malignancy 18 (75%) 14 (73.7%) 4 (80%) 0.99
Cancer status
Controlled/remission 3 (12.5%) 3 (15.8%) 0 0.99
Active - newly-diagnosed 9 (37.5%) 6 (31.6%) 3 (60%) 0.32
Active – recurrence/progression 12 (50%) 10 (52.6%) 2 (40%) 0.99
Performance status
0–1 6 (31.6%) 6 (31.6%) 0 0.28
2–4 18 (75%) 13 (68.4%) 5 (100%) 0.28
Previous chemotherapy 18 (75%) 13 (54.2%) 5 (100%) 0.28
Previous use of corticosteroids 14 (58.3%) 10 (52.6%) 4 (80%) 0.36
Neutropenia 14 (58.3%) 7 (36.8%) 3 (60%) 0.67
Need for mechanical ventilation 10 (41.6%) 5 (26.3%) 5 (100%) 0.06
Presence of extra-pulmonary organ dysfunction 8 (33.3%) 4 (21.1%) 4 (80%) 0.03
Oseltamivir treatment duration (days) 7 (0–19) 9 (1–19) 5 (1–18) 0.38
aResults are expressed as the mean 6 standard deviation, median (range), n (%).
bReported P values refer to comparisons between survivors and non-survivors.
doi:10.1371/journal.pone.0014158.t001
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Figure 2. Time course of viral shedding in hospitalized cancer patients.
doi:10.1371/journal.pone.0014158.g002
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divergence was found in the H1N1pdm isolates collected during
the onset of illness from the four patients with prolonged shedding
(Figure S1).
To evaluate the genetic characteristics of the isolates from
patients with prolonged viral shedding, we sequenced two
consecutive samples from a single individual (5645s2/09 and
5645s3/09) and compared their HA sequences to other H1N1pdm
viruses from mild, severe and fatal cases from different countries.
We observed that samples collected a month apart (5645s2/09 and
5645s3/09) clustered together and displayed a relatively large
branch length from other H1N1pdm viruses (Figure 3). This result
may have occurred because strain 5645s2/09 diverged from CA/
Figure 3. Phylogenetic tree of H1N1pdm strains from HCI-INCa and other Brazilian strains based on the HA gene. The bootstrap
probability is indicated for each interior branch, and values below 80% are hidden. The scale bar indicates the number of amino acid changes per site.
The sampling number and the state of origin in Brazil are displayed. This tree is rooted by the California/04/2009 HA sequence.
doi:10.1371/journal.pone.0014158.g003
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04 in the amino acid residues L52S, L70P, P100S, C153L, T214A,
Q293R and I321V (H1 numbering). Additionally, isolate 5645s3/
09, which was sequenced from amino acid residues 167 to 413,
also had the mutations T214A, Q293R and I321V fixed in the
viral population a month after the initial sampling. In the isolate
5645s3/09, another mutation was also acquired, D238P, suggest-
ing continuous viral evolution. Although we cannot determine the
role of these mutations in viral pathogenesis by this result alone,
the retention of the changed residues over time strongly suggests
viral persistence rather than re-infection.
H1N1pdm susceptibility to oseltamivir
Considering that influenza resistance to antivirals is likely to
emerge in immunocompromised individuals and that, with respect
to the H1N1pdm virus, only a few studies have detected
oseltamivir resistance [20], we investigated the emergence of
antiviral resistance in H1N1pdm samples isolated in cell culture.
Thus, oseltamivir carboxylate IC50 values were measured for 15
H1N1pdm samples isolated from 13 patients. We found that 10
isolates were sensitive (0.8560.27 nM), and 5 displayed high IC50
values for the antiviral used (165.13642.26 nM). These samples
were sent to the WHO collaborating center at the CDC in Atlanta
for resistance confirmation. We found that the isolates with high
IC50 values were endowed with a neuraminidase (NA) activity that
was cross-resistant to oseltamivir, zanamivir and peramivir,
suggesting the presence of a co-pathogen endowed with NA
activity within these isolates. Co-infections with other respiratory
viruses (coronavirus (229, 43 and 63), parainfluenza (1, 2, 3 and 4),
human metapneumovirus, parechovirus, rhinovirus, RSV A/B,
adenovirus and enterovirus) or atypical bacteria (Mycobacterium
pneumonia) were not identified in these samples, suggesting that no
other viral source of NA activity was responsible for these high
IC50 values. However, we co-isolated a Streptococcus sp. from the
samples with high IC50 values. The NA activity of this bacterial
strain displayed a phenotype resistant to NAIs. In further testing
with bacteria-free H1N1pdm isolates, the virus’ IC50 were
consistent with a sensitive isolate. Pyrosequencing analyses were
also performed and revealed that the other high-IC50 samples had
the WT H275 residue and thus did not contain this oseltamivir
resistance marker. Viruses isolated from the initial onset of illness
were A/California/07-like viruses (Figure S2).
Discussion
Prolonged influenza shedding in cancer patients has been
observed for seasonal strains [15]. Regarding the H1N1pdm virus,
it has been shown that prolonged virus shedding in cancer patients
may occur, although such a phenomenon has only been
documented through cases involving a single studied patient
[21,22,23,24,25]. Here, we prospectively and systematically
collected information from a cohort of hospitalized cancer patients
with severe H1N1pdm infections. These patients presented high
mortality, prolonged viral shedding and H1N1pdm evolution
without the emergence of oseltamivir resistance. This is the first
study to address viral shedding and resistance in cancer patients
with H1N1pdm infections; thus, it may provide insight into the
role of cancer patients as potential human reservoirs for this
pandemic virus.
Unlike previous reports, our population was composed of
hospitalized, severely immunocompromised cancer patients [26].
Most of them were young, had hematologic malignancies and
received chemotherapy and systemic steroids in the weeks that
preceded the H1N1pdm infection. The patients were treated with
oseltamivir in the early course of the infection (the median time to
antiviral initiation was three days). A total of 13 patients (54%)
required intensive care and presented severe respiratory distress.
In these patients, the mortality rates were higher (38%) than those
observed for general ICU patients suffering from H1N1pdm
infections [2,27] as well as for non-critically ill cancer patients [26].
However, the outcomes were not different from those reported for
cancer patients requiring mechanical ventilation [28,29].
Interestingly, during the influenza season, 14 patients (58.3%)
with febrile neutropenia were identified as H1N1pdm cases, a
condition that is not usually investigated in this scenario. However,
febrile neutropenic cancer patients have an increased risk of
Table 2. Comparisons of the period of viral shedding in the general, hospitalized and immunocompromised populations.
General Population Hospitalized Immunocompromised
Authors Cowling
et al.
Hien
et al.
De Serres
et al.
Fleury
et al.
Witkop
et al.
Cao
et al.
Seville
et al.
CDC Ours
Reference [31] [33] [34] [25] [22] [23] [32] [21]
General population Households,
Hong Kong
Containment of
the pandemics in
Ho Chi Minh City
(HCMC), Vietnam
Households,
Canada
Travelers,
France
Military
cadets
First 426
patients
hospitalized
in China
No No No
Immunocompromised ND ND ND No ND ND Yes Yes Yes
Underlying disease ND ND ND No ND Various Transplant
recipients
Leukemia Cancer
Number of patients evalu-
ated for virus shedding
54 932 43 2 29 350 6 2 10
Number of patients with
virus shedding $7 days
2 children ,80 8–14b 2 7 238 1 2 5
Highest period of shed-
ding (days)
8 11–12a 8–11b 14–28c 9 17 11 37–44c 63
a– Five to six days for children under nine years old.
b– Eight patients shed the virus for at least 8 days, while 14 shed for at least 11 days.
c– Only two patients were evaluated.
ND – Not determined.
doi:10.1371/journal.pone.0014158.t002
H1N1 in Cancer Patients
PLoS ONE | www.plosone.org 6 November 2010 | Volume 5 | Issue 11 | e14158
developing respiratory distress and multi-organ failure. Therefore,
screening for respiratory viruses and prompt initiation of
oseltamivir treatment should be considered in these patients.
Febrile neutropenia indicates a poor prognostic with respect to a
patient’s outcome, but neutropenia duration in our cohort of
patients was less than seven days. Thus, prolonged viral shedding
might not have a correlation with neutropenia.
We observed the persistence of H1N1pdm in 5 out of 10
patients studied for this purpose. In these individuals, viral
shedding continued for at least 11 days, despite the use of
oseltamivir. The median duration of viral shedding in our
population was 23 days, and two pediatric patients with acute
lymphoblastic leukemia showed even longer virus secretions (44
and 63 days; Figure 2 and Table S10), although it is difficult to
determine whether viral persistence was due to cancer per se or to
acute lung injury and mechanical ventilation.
Influenza shedding is not considered to last long, and it
disappears seven days after the onset (2.4 and 4.5 days for
oseltamivir- and placebo-treated groups, respectively) [30]. Studies
aimed at monitoring 2009 H1N1pdm virus shedding using
randomized trials with appropriate controls, such as outpatients
and hospitalized or immunocompromised individuals, have not yet
been conducted. Because we were also unable to establish age-
matched controls with or without immunosuppression, since this
study was conducted during the peak of the first wave of the 2009
pandemics in Brazil, we compared our work to other studies on
H1N1pdm shedding in general, hospitalized or immunocompro-
mised populations [21,22,23,24,25,31,32,33,34,35,36]. In Table 2,
we summarize the cohort used in each study, whether or not they
were immunocompromised, their underlying diseases and the
number of patients analyzed for viral shedding in each of these
studies. We compared the maximum periods of shedding among
these different populations and the number of patients that
secreted the virus for more than seven days. These data would be
more informative and relevant from a public health point of view
because the duration of the quarantine for H1N1pdm was
approximately that long [21]. We found (Table 2) that in
households in Hong Kong [31] and Canada [34], the maximum
periods of H1N1pdm shedding ranged from 8 to 11 days. These
periods were not different from what was observed with military
cadets [22] and during the containment phase of the pandemics in
Vietnam [23] (Table 2). Regarding H1N1pdm shedding among
infants, Hien et al. showed that children five to nine years old
could secrete the H1N1pdm virus for five to six days, which is
markedly lower than what is observed for the seasonal influenza
virus [30,33]. Compared to our results, we observed higher
periods of viral shedding in two seven-year-old patients with acute
lymphoblastic leukemia (Table 2 and Figure 2). However, a single
report on two travelers in France showed that these apparently
immunocompetent individuals secreted the H1N1pdm virus for 14
and 28 days [25] (Table 2). Although these periods of time are
comparable to the time frame of virus secretion in hospitalized
patients in China [23] and our work, the study from Felury et al.
might be as biased as ours by the small size of the cohort (Table 2).
Influenza-infected immunocompromised individuals may have
prolonged influenza shedding [15,21,32,36]; however, more
insights are necessary to better comprehend the dynamics of the
H1N1pdm virus in these individuals. Mora et al. showed that in
HIV-1-infected individuals, co-infection with the H1N1pdm virus
might lead to an outcome not different from the one expected for
immunocompetent subjects, although no systematic analysis of
viral shedding was performed [36]. A similar conclusion was also
drawn for transplant recipient individuals, whose longest periods
of viral shedding did not exceed 11 days [32] (Table 2). In our
study, we found periods of H1N1pdm shedding similar to what the
CDC observed for leukemia patients [21] (Table 2). Although the
small size of these cohorts of immunocompromised individuals
[21,32], including ours, may require a more conclusive and
mechanistic analysis, these observations may stimulate further
systematic studies to understand or gain insight into factors
associated with prolonged H1N1pdm shedding. In addition, it
might give insights on basic studies on influenza pathogenesis.
Our results highlight the need for closer surveillance of cancer
patients with H1N1pdm infections until the detection of the first
negative sample. We hypothesize that follow-up protocols aimed at
monitoring the persistence of viral shedding in cancer patients may
be relevant if patients are submitted to immunosuppressive
therapies in the days or weeks prior to or following an H1N1pdm
infection.
Next, we sought to determine viral evolution during prolonged
shedding. We found that some amino acid changes persisted from
the initial symptoms until 30 days thereafter, suggesting that these
patients had viral persistence rather than re-infection. In addition,
an extra amino acid change (D238P) was found in the viral HA
sequenced a month after the onset of illness, suggesting continuing
viral evolution. Although some of the mutations that we found
(L52S, L70P, P100S, C153L, T214A, D238P, Q293R and I321V)
in strains 5645s2/09 and 5645s3/09 have not been previously
described, other amino acid residue changes that were detected in
our study (P100S and T214A) have been found in H1N1pdm
viruses throughout the world without a significant link to viral
pathogenesis or antigenic variation [37,38,39].
Influenza viruses resistant to antiviral drugs have been reported
in immunocompromised patients, [21,40] and this resistance
might be associated with prolonged viral shedding [41,42].
Notably, five isolates from two patients had high IC50 values to
neuraminidase inhibitors (NAIs). An NA activity that was multi-
resistant to NAIs was identified and could be due to the presence
of a Streptococcus strain found in throat swabs and tracheal aspirates.
Pyrosequencing analyses of samples with high IC50 values revealed
that these specimens were H275 wild-type sensitive viruses. These
results reinforce the need for additional genotyping assays to
confirm the identification of putative resistant strains identified
using functional assays. In addition, our findings show the need for
investigating other sources of NA activity in virus isolates with odd
IC50 values.
The apparent paradox of prolonged viral shedding without
antiviral resistance could be explained by either the inability of the
immunocompromised host to effectively clear the H1N1pdm virus
[12,43] or inefficient absorption of the drug [44]. Because we
combined both clinical and molecular virology data, our results
might contribute to the discussion on the adequate duration and
type of anti-H1N1pdm treatment in immunocompromised patients
with a protracted course. In these patients, the use of parenteral
systemic or inhaled antivirals should also be investigated.
Although our work further investigates the unique dynamics of
H1N1pdm virus infection in immunocompromised hosts, some
caveats must be noted. Because our investigation started during a
new pandemic, the clinical evaluation and management protocols
changed during the course of the study as new data emerged from
the literature and from updated recommendations [45]. As the
pandemic reached its peak in South America, the establishment of
a larger and more diverse cohort with age-matched controls with
or without immunosuppression became complex. Thus, more in-
depth multivariate and mechanistic clinical analyses were limited.
Moreover, no recommendations for monitoring viral persistence
were available; therefore, only a subset of severely ill patients
admitted to the ICU was evaluated. Despite that, an important
H1N1 in Cancer Patients
PLoS ONE | www.plosone.org 7 November 2010 | Volume 5 | Issue 11 | e14158
connection between clinical and laboratory information was
studied, revealing the continuous evolution of H1N1pdm HA
sequences and the stability of the NA gene in severely ill patients
[14].
In conclusion, this study provides evidence that severe
H1N1pdm infection is associated with significant morbidity and
mortality in cancer patients. In these patients, viral persistence
without the emergence of antiviral resistance may occur during the
clinical course of the disease. This result has major implications for
the clinical management of H1N1pdm infections and infection
control strategies. Our study may provide insights into H1N1pdm
shedding and might contribute to the development of new
guidelines to manage cancer patients with H1N1pdm infection.
Methods
Ethics statement
The Ethics Committee (Comiteˆ de E´tica em Pesquisa; CEP;
http://www.inca.gov.br/conteudo_view.asp?id = 2380) at the In-
stituto Nacional de Caˆncer (INCa), Rio de Janeiro, Brazil, headed
by Dr. Adriana Scheliga approved the study under protocol #18/
2010 and waived the need for informed consent.
Design and setting
This was a prospective cohort study conducted in the Hospital
do Caˆncer-I, Instituto Nacional de Caˆncer (HC-I-INCa), Rio de
Janeiro, Brazil, from July 8th to October 1st, 2009. The HCI-INCa
is a 160-bed comprehensive cancer center primarily for the
population of Rio de Janeiro and neighboring states. The present
study was strictly observational, and every clinical decision was at
the discretion of the attending physician.
Patients, data collection and definitions
All patients with a definite diagnosis of cancer requiring hospital
admission for any reason and who displayed influenza-like illness
were evaluated. Patients in complete remission from cancer for
more than five years were not considered.
Data were collected using a standardized case report form that
included demographic data, clinical presentation, comorbidities,
cancer status, use of immunosuppressive therapies, time course of
acute illness, need for intensive care, use of antivirals, adjunctive
therapies, advanced life support and in-hospital mortality
(supporting information; SI). Patients were included if they had
a fever (.37.8uC) and/or respiratory influenza-like illness and
confirmed influenza A H1N1pdm diagnosis (by at least one of
three assays, IFI, rRT-PCR or cell culture, and according to case
definitions from the WHO [46]). Patients were treated according
to the Brazilian Public Health guidelines [47].
Sample collection and analysis
Nasopharyngeal Dacron-swab specimens were collected from
all patients and placed onto transport medium (Hanks solution
with 100 U/mL penicillin and 100 mg/mL streptomycin) at the
initial evaluation. Tracheal aspirates were also obtained if the
patient required tracheal intubation. Patients’ clinical samples
were directly tested for a panel of respiratory viruses using an IFI
assay for influenza A (respiratory virus panel; Biotrin, Mount
Merrion, Co. Dublin, Ireland.). Specimens were also sent to the
Brazilian National Influenza Center (IOC/Fiocruz) for H1N1pdm
confirmation using rRT-PCR, which was performed in accor-
dance with the current guidelines from the WHO/CDC [46].
Viral shedding was evaluated in the subset of patients that
remained under mechanical ventilation for longer than seven days
and in those patients with persistent hypoxemia and pulmonary
infiltrate. These patients received a specific number to which their
sample number was appended. That is, the first sample was ‘‘s1’’,
and subsequent specimens were numbered consecutively (Table
S12). Viral secretion was evaluated using both cell culture and
rRT-PCR assays until it was negative. Virus isolation was
performed in Madin-Darby canine kidney (MDCK) cells and/or
embryonated eggs (see Text S1 and Table S12). The functional
antiviral assay was performed using the NA-Star kit (Applied
Biosystems, CA), according to the manufacturer’s instructions.
The RT-PCR protocol for sequencing using the Sanger method
and pyrosequencing [48] are presented in the SI, as well as the
phylogenetic analysis.
Blood samples were routinely sent for bacterial culturing, as
were tracheal aspirates if the patient was intubated.
Statistical analysis
Standard descriptive statistics were used to describe the study
population. Continuous variables were reported as the mean 6
standard deviation or median (range) as appropriate. Univariate
analysis was used to identify factors associated with hospital
mortality. Two-sample t-tests and a chi-square or Fisher’s exact
test were also used. Two-tailed P values ,0.05 were considered
statistically significant.
Supporting Information
Text S1 Clinical investigation and Influenza virus assays.
Found at: doi:10.1371/journal.pone.0014158.s001 (0.06 MB
DOC)
Table S1 Diagnostic tests for Influenza A virus.
Found at: doi:10.1371/journal.pone.0014158.s002 (0.04 MB
DOC)
Table S2 Patient’s characteristics and outcomes according to
age range.
Found at: doi:10.1371/journal.pone.0014158.s003 (0.04 MB
DOC)
Table S3 Prevalence of underlying malignancies.
Found at: doi:10.1371/journal.pone.0014158.s004 (0.03 MB
DOC)
Table S4 Use of Chemotherapy, corticosteroids and granulocyte
colony stimulating factor previous to H1N1pdm infection.
Found at: doi:10.1371/journal.pone.0014158.s005 (0.04 MB
DOC)
Table S5 Patient’s Neutropenia.
Found at: doi:10.1371/journal.pone.0014158.s006 (0.04 MB
DOC)
Table S6 Oseltamivir treatments.
Found at: doi:10.1371/journal.pone.0014158.s007 (0.03 MB
DOC)
Table S7 Focus of bacterial infection in cancer patients with
Influenza A H1N1pdm.
Found at: doi:10.1371/journal.pone.0014158.s008 (0.03 MB
DOC)
Table S8 Bacteria isolates from cancer patients with Influenza A
H1N1pdm.
Found at: doi:10.1371/journal.pone.0014158.s009 (0.03 MB
DOC)
Table S9 Organ Dysfunctions 72 h after H1N1pdm diagnosis.
Found at: doi:10.1371/journal.pone.0014158.s010 (0.03 MB
DOC)
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Table S10 Frequency of signs and symptoms at clinical
suspicion.
Found at: doi:10.1371/journal.pone.0014158.s011 (0.03 MB
DOC)
Table S11 Pulmonary infiltrates at Influenza diagnosis and
hospital discharge, by chest radiography.
Found at: doi:10.1371/journal.pone.0014158.s012 (0.03 MB
DOC)
Table S12 Clinical and Viral Characteristics of the followed-up
cohort.
Found at: doi:10.1371/journal.pone.0014158.s013 (0.08 MB
DOC)
Figure S1 Phylogenetic tree of HA gene from the classical swine,
Eurasian swine, American Avian and human seasonal lineages.
The bootstrap probability is indicated for each interior branch, all
values below 80% are hidden. The scale bar indicates the number
of amino acid changes per site. Colored circles indicate the
samples from our study. This tree is unrooted. Each Influenza HA
lineage is displayed beside their respective clade.
Found at: doi:10.1371/journal.pone.0014158.s014 (0.12 MB TIF)
Figure S2 Phylogenetic tree of NA gene from the followed-up
cohort. The bootstrap probability is not indicated for each interior
branch since it is below 85%. The scale bar indicates the number
of amino acid changes per site. The tree is rooted by California/
07/2009 NA sequence.
Found at: doi:10.1371/journal.pone.0014158.s015 (0.18 MB TIF)
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